Abstract: A method for simultaneously detecting scattered light, deflected light, or a combination thereof from a target in a subject at a plurality of locations, the method including: placing a sensor head on the subject proximal the target, the sensor head including: a housing; an illumination output coupled to an illumination source; a plurality of light collection units each comprising one or more polished ends of one or more respective optical fibers, each light collection unit disposed at a respective predetermined radial distance from the illumination output; wherein a number of polished ends in each light collection unit corresponds to the respective predetermined radial distance; generating, with the illumination source, the light energy; collecting, with at least one of the light collection units, at least one of scattered light and/or refracted light to provide collected light; and passing at least a portion of the collected light through a spectrometer.

Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig's disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig’s disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig's disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: A device and system for non-invasively measuring wavelength-dependent changes in optical absorption of brain tissue damaged by CTE, TBI, concussion, repetitive trauma, and/or Lou Gehrig's disease in comparison to signals from healthy normal tissue for a subject in vivo. The brain, tissues, and fluids superficial to the brain are trans-cranially illuminated by light source(s) in low-absorption spectral windows for tissue in the visible and/or near-infrared parts of the spectrum. Optode(s) are disposed at predetermined radial distance(s) from a light output to collect the scattered and/or deflected signal from the surface of the head. The predetermined radial distance from the light output to the optode is correlated with the depth of tissue penetration for the light collected by the optode. A spectrometer and computer analyze the collected light for characteristic optical signatures of the brain tissue damage utilizing the absorbance and/or reflectance and/or transmission spectra generated as a result.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.

Abstract: The invention provides methods of treating, preventing, delaying the onset, slowing the progression, or reversing the symptoms of Alzheimer's disease and other neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide. The invention also provides compounds that reduce the production or secretion of the A?42-peptide by cells, and pharmaceutical compositions comprising such compounds, for the treatment of neurodegenerative diseases characterized by the accumulation of amyloid plaques comprising the A?42 peptide.

Abstract: Novel PN7718 protein and nucleic acids encoding PN7718 are provided. PN7718-containing protein complexes formed by PN7718 and a PN7718-interacting protein (e.g., cyclophilin C) are also provided. Cyclophilin C and PN7718 may be involved in common biological processes such as intracellular calcium signaling, beta-amyloid formation, T-cell receptor and IgE receptor signaling pathways, and protein folding and degradation. Thus, the protein complexes as well as PN7718 can be used in screening assays to select modulators of PN7718 and the protein complexes formed by PN7718 and cyclophilin C. The identified modulators can be useful in modulating the functions and activities of PN7718 and protein complexes containing PN7718, and in treating and preventing autoimmune diseases, neurological diseases and cardiovascular disorders.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Protein complexes are provided comprising MAP17 and SCAMP2. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with MAP17 and SCAMP2. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Abstract: The present invention generally relates to methods and compositions for treating neurological disorders and diseases. In addition, methods for selecting therapeutic agents useful for treating neurological disorders and diseases are provided.

Abstract: Protein complexes are provided comprising at least one interacting pair of proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes, and in treating and/or preventing diseases and disorders associated with the protein complexes and/or their constituent interacting members.

Abstract: Protein complexes are provided comprising APOA2 and one or more APOA2-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA2 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Abstract: Protein complexes are provided comprising Caspase-7 and a Caspase-7-interacting protein. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with Caspase-7 and the Caspase-7-interacting protein. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Abstract: Protein complexes are provided comprising APOA1 and one or more APOA1-interacting proteins. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with APOA1 and its interacting partners. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

Abstract: Protein complexes are provided comprising BCL-XL and TCTP. The protein complexes are useful in screening assays for identifying compounds effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with BCL-XL and TCTP. In addition, methods for detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.